Poster Hall
Sponsored by AbbVie Medical Affairs
Psoriatic arthritis
6 months 3 weeks ago
Combination of GOL/MTX was not significantly superior in reducing PASDAS-measured disease activity at 24 weeks. First line treatment of early, DMARD naïve PsA with MTX 25 mg/week and CS produced effective disease control. There was low utilisation of bDMARDs at 52 weeks in both… https://t.co/aEg9rw4evM https://t.co/prDtnHm793
6 months 3 weeks ago
Synovial tissue specimens were processed for H&E-based semiquantitative synovitis quantification (KSS) in biopsies in PsA. KSS was significantly higher in cs/b-DMARDs resistant patients than naive PsA(p<0.0001) and PsA in remission/LDA (p<0.0001). KSS directly correlated with… https://t.co/cHIw8zRByK https://t.co/vppmG7JwC8
6 months 3 weeks ago
In a Swedish-Danish cohort study on patients with PsA, treatment with TNFi was associated with a small increased risk of NMSC and with non-significant numeric risk increases for both BCC and SCC compared with bDMARD naïve #EULAR2024 Abstract 0150 @RheumNow https://t.co/vC4pgSKmfY
6 months 3 weeks ago
Can we prevent psoriatic arthritis? Highlights from #EULAR2024 that help us understand this topic better @RheumNow https://t.co/E8Wy8FH4oU
Wednesday was Day One at EULAR 2024 in Vienna. While the day was a slow start, the poster halls and auditoriums quickly filled with thousands of rheumatologists, eager to reunite at this…
Psoriatic arthritis (PsA) can affect up to 30% of patients with psoriasis (PsO). Understanding the factors that predispose patients with PsO who progress to PsA is the first step in understanding how…
6 months 3 weeks ago
200 millions pts PSO
1st line, Reduction risk PsA: IL 12-23 37% & IL-23 39% vs. TNFi
2nd line ttmt, IL12-23i 32% & IL-23i 31%
IL-23i 47% lower proba PsA than IL-17i 3 & 5 yrs
Can't exclude some channeling bias, but that's a big signal!
@RheumNow OP0010 #EULAR2024 #EULARBest
